Go | New | Find | Notify | Tools | Reply | |
| Member |
The first year of price reduction will be 2026. Of course big Pharma is fighting this. Here is the list: Subject to negotiation in 2026 1 D Eliquis Apixaban BMS/Pfizer 9,936,069,814 13.0 2028 25 3.7 billion 2 D Xarelto Rivaroxaban Janssen Pharm. 4,701,314,805 14.5 2027 25 3 D Januviaf Sitagliptin phosphate Merck Sharp & D 3,865,087,773 19.2 2026 60 4 D Imbruvica Ibrutinib Pharmacyclics 2,962,909,304 12.1 2033 25 5 D Jardiance Empagliflozin Boehringer Ing. 2,376,166,292 11.4 2028 25 6 D Enbrel Etanercept Amgen 2,154,714,778 27.2 2029 60 7 D Symbicort Budesonide/formoterol Astrazeneca 2,135,408,250 19.5 2028 60 8 D Ibrance Palbociclib Pfizer US Pharm 2,108,937,188 10.9 2034 25 9 D Xtandi Enzalutamide Astellas Pharma 1,968,567,948 13.4 2027 25 10 D Breo Ellipta link: https://thehill.com/policy/hea...-negotiations-heres- | ||
|
Truth Seeker |
Interesting. My mom is taking #4 Imbruvica for Leukemia. It has saved, or prolonged, her life. It is absurd how much this drug costs. It would normally be about $12,000 per month for her. She was lucky to be accepted into a grant program that pays for it. At full strength it caused her horrible side effects, but she has found a happy medium to where this drug is really helping her. If it was not for this grant, she would be dead. Medicare or any other insurance should pay for this, and it shouldn’t be this expensive. NRA Benefactor Life Member | |||
|
| Powered by Social Strata |
 | Please Wait. Your request is being processed... |
|
© SIGforum 2024